Back to results
US 2016/0096824 A1Published application
Heterocyclic Compounds Useful for Kinase Inhibition
AssigneeAmitech Therapeutic Solutions, Inc.
InventorsLee Daniel ARNOLD, Eric A. MURPHY
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds useful for kinase inhibition.
Claims82
A compound having the structure (I) or an N-oxide, N,N′-dioxide, N,N′,N″-trioxide, or a pharmaceutically acceptable salt thereof:
- wherein:
- Q is O or S;
- W is C6-C12 aryl or C3-C12 heteroaryl having 1-3 heteroatoms;
- each of X and Y is independently absent or a NH;
- each of Z1 and Z2 is independently selected from a group consisting of CH, N, and NR5, wherein R5 is hydrogen or lower alkyl;
- Z3 is O, S, N, or NR5, wherein R5 is hydrogen or lower alkyl;
- R1 is an unsubstituted or a substituted C3-C12 heteroaryl having 1-3 heteroatoms or an alkyl substituted with an unsubstituted or a substituted C3-C12 heteroaryl having 1-3 heteroatoms;
- each R2 and R3 are independently selected from a group consisting of a hydrogen, a C1-C6 alkoxy, an optionally substituted C1-C6 alkyl, an optionally substituted C3-C12 cycloalkyl, an optionally substituted C3-C10 heterocycle having 1-3 heteroatoms, an optionally substituted C6-C12 aryl, an optional substituted C3-C12 heteroaryl having 1-3 heteroatoms, CF3, halogen, CN, CONHR6 and CO2R′ wherein R′ is hydrogen or C1-C6 alkyl;
- or, optionally, R2 and R3 are joined to form a five to seven membered carbocycle;
- R4 is independently selected from a group consisting of hydrogen, halogen, C1-C6 alkyl, —OH, NO2, —CN, C1-C6 alkoxy, —NHSO2R6, —SO2NHR6, —NHCOR6, —NH2, —NR6R7, —SR6, —S(O)R6, —S(O)2R6, —CO2R6, —CONR6R7, wherein R6 and R7 are independently selected from a group consisting of hydrogen, and an optionally substituted C1-C6 alkyl;
- p=0-4;
- and n is 1 or 2.
9 more elements
A compound having the structure (IV) or an N-oxide, N,N′-dioxide, N,N′,N″-trioxide, or a pharmaceutically acceptable salt thereof:
- wherein:
- each of Z1 and Z2 is independently selected from a group consisting of CH, N, and NR5, wherein R5 is hydrogen or lower alkyl;
- Z3 is O, S, N or NR5, wherein R5 is hydrogen or lower alkyl;
- R1 is an unsubstituted or a substituted C3-C12 heteroaryl having 1-3 heteroatoms or an alkyl substituted with an unsubstituted or a substituted C3-C12 heteroaryl having 1-3 heteroatoms;
- R4 is independently selected from a group consisting of hydrogen, halogen, C1-C6 alkyl, —OH, —NO2, —CN, C1-C6 alkoxy, —NHSO2R6, —SO2NHR6, —NHCOR6, —NH2, —NR6R7, —SR6, —S(O)R6, —S(O)2R6, —CO2R6, —CONR6R7, wherein R6 and R7 are independently selected from a group consisting of hydrogen, and an optionally substituted C1-C6 alkyl and n is 1 or 2;
- and
- R13 is an optionally substituted N—(C1-C6 alkyl)pyrazolyl or selected from a group consisting of the following structures:
4 more elements
A compound having the structure (V) or an N-oxide, N,N′-dioxide, N,N′,N″-trioxide, or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is an unsubstituted or a substituted C3-C12 heteroaryl having 1-3 heteroatoms or an alkyl substituted with an unsubstituted or a substituted C3-C12 heteroaryl having 1-3 heteroatoms;
- R4 is independently selected from a group consisting of hydrogen, halogen, C1-C6 alkyl, —OH, —NO2, —CN, C1-C6 alkoxy, —NHSO2R6, —SO2NHR6, —NHCOR6, —NH2, —NR6R7, —SR6, —S(O)R6, —S(O)2R6, —CO2R6, and —CONR6R7, wherein R6 and R7 are independently selected from a group consisting of hydrogen, and an optionally substituted C1-C6 alkyl;
- n is 1 or 2;
- and
- R14 is selected from a group consisting of an optionally substituted C1-C12 alkyl, an optionally substituted C3-C12 cycloalkyl, an optionally substituted C3-C10 heterocycle having 1-3 heteroatoms, an optionally substituted C6-C12 aryl, and an optional substituted C3-C12 heteroaryl having 1-3 heteroatoms.
3 more elements
A pharmaceutical composition comprising a compound as set forth in any of the preceding claims, in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.